Kashihara, Japan
Kashihara, Japan

Nara Medical University is a public university in Kashihara, Nara, Japan. The predecessor of the university, Nara Medical College , was founded in April 1945. Wikipedia.


Time filter

Source Type

Patent
Chugai Seiyaku Kabushiki Kaisha and Nara Medical University | Date: 2015-08-05

Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.


Patent
Kawasumi Laboratories Inc. and Nara Medical University | Date: 2014-12-10

The purpose of the present invention is to provide a biliary stent making it possible to sufficiently exhibit a valve function while reducing the entire length of the biliary stent as compared to conventional ones. The present invention is a biliary stent (1) including a stent body (10), a tubular membrane (30) on one end of the stent body (10) and having a bile outflow port (34), and two support members (40, 50) which at one end (42, 52) are connected to the one end of the stent body (10) and at the other end (44, 54) are connected to the vicinity of the bile outflow port (34).


Patent
Nara Medical University and Sysmex Corporation | Date: 2015-12-15

Disclosed is a blood sample determination method including: emitting light to a measurement specimen prepared by mixing a clotting time measuring reagent and a blood sample suspected to be derived from a subject having lupus anticoagulant or a coagulation factor inhibitor, to obtain optical information about an amount of light from the measurement specimen; obtaining at least one parameter regarding derivative of clot waveform, based on the obtained optical information; and determining, based on a value of the obtained parameter, whether the blood sample is suspected to be a sample derived from a subject having lupus anticoagulant or is suspected to be a sample derived from a subject having a coagulation factor inhibitor.


Patent
Cosmed Pharmaceutical Co., Osaka University and Nara Medical University | Date: 2013-11-01

An object to be achieved by the present invention is to provide a microneedle array which is able to supply effectively retinoic acid to the skin and effective in treating pimples, stains or wrinkles. The retinoic acid microneedle array comprises: a microneedle array having a microneedle substrate 5 and microneedles 1 disposed on the microneedle substrate 5; and a drug retained on the microneedles 1 and containing a water-swelling polymer and retinoic acid.


Patent
Cosmed Pharmaceutical Co., Osaka University and Nara Medical University | Date: 2015-09-09

An object to be achieved by the present invention is to provide a microneedle array which is able to supply effectively retinoic acid to the skin and effective in treating pimples, stains or wrinkles. The retinoic acid microneedle array comprises: a microneedle array having a microneedle substrate 5 and microneedles 1 disposed on the microneedle substrate 5; and a drug retained on the microneedles 1 and containing a water-swelling polymer and retinoic acid.


Estrogen-DNA adducts are potential biomarkers for assessing the risk and development of estrogen-associated cancers. 4-Hydroxyequilenin (4-OHEN) and 4-hydroxyequilin (4-OHEQ), the metabolites of equine estrogens present in common hormone replacement therapy (HRT) formulations, are capable of producing bulky 4-OHEN-DNA adducts. Although the formation of 4-OHEN-DNA adducts has been reported, their quantitative detection in mammalian cells has not been done. To quantify such DNA adducts, we generated a novel monoclonal antibody (4OHEN-1) specific for 4-OHEN-DNA adducts. The primary epitope recognized is one type of stereoisomers of 4-OHEN-dA adducts and of 4-OHEN-dC adducts in DNA. An immunoassay with 4OHEN-1 revealed a linear dose-response between known amounts of 4-OHEN-DNA adducts and the antibody binding to those adducts, with a detection limit of approximately five adducts/10(8) bases in 1 microg DNA sample. In human breast cancer cells, the quantitative immunoassay revealed that 4-OHEN produces five times more 4-OHEN-DNA adducts than does 4-OHEQ. Moreover, in a mouse model for HRT, oral administration of Premarin increased the levels of 4-OHEN-DNA adducts in various tissues, including the uterus and ovaries, in a time-dependent manner. Thus, we succeeded in establishing a novel immunoassay for quantitative detection of 4-OHEN-DNA adducts in mammalian cells.


Osaki S.,Nara Medical University
Physical Review Letters | Year: 2012

We overcome the difficulties in pulling long draglines from spiders, twist bundles of dragline filaments, and succeed in preparing violin strings. The twisting is found to change the cross section shapes of filaments from circular to polygonal and to optimize the packing structure with no openings among filaments providing mechanically strong and elastic strings. The spider string signal peaks of overtones for the violin are relatively large at high frequencies, generating a soft and profound timbre. Such a preferable timbre is considered to be due to the unique polygonal packing structure which provides valuable knowledge for developing new types of materials. © 2012 American Physical Society.


Fukui H.,Nara Medical University
World Journal of Hepatology | Year: 2015

A "leaky gut" may be the cutting edge for the passage of toxins, antigens or bacteria into the body, and may play a pathogenic role in advanced liver cirrhosis and its complications. Plasma endotoxin levels have been admitted as a surrogate marker of bacterial translocation and close relations of endotoxemia to hyperdynamic circulation, portal hypertension, renal, cardiac, pulmonary and coagulation disturbances have been reported. Bacterial overgrowth, increased intestinal permeability, failure to inactivate endotoxin, activated innate immunity are all likely to play a role in the pathological states of bacterial translocation. Therapeutic approach by management of the gut-liver axis by antibiotics, probiotics, synbiotics, prebiotics and their combinations may improve the clinical course of cirrhotic patients. Special concern should be paid on anti-endotoxin treatment. Adequate management of the gut-liver axis may be effective for prevention of liver cirrhosis itself by inhibiting the progression of fibrosis. © 2015 Baishideng Publishing Group Inc.


On March 11, 2011 eastern Japan was struck by a magnitude 9.0 earthquake and an enormous tsunami, over 13 m in height, which together killed over 20,500 people and resulted in the evacuation of over 320,000 people from the devastated areas. This paper describes the damage sustained by the Fukushima-Daiichi nuclear power plant during this unpredicted major natural disaster and the events that happened in the months after this accident. The events occurring at the Fukushima-Daiichi nuclear power plant, the actions taken to minimize the effects of the damage to the plant and to protect the public, and the points at which the responses proved to be inadequate all offer lessons that will be of value to those planning for and responding to future natural disasters and accidents in Japan and around the world. © 2012 by Radiation Research Society.


Patent
Nara Medical University | Date: 2015-08-26

The present invention provides a novel cancer marker that is useful in the diagnosis of urothelial cancer. The present invention uses ubiquilin 2 as a cancer marker for urothelial cancer (renal pelvis cancer, ureteral cancer, and bladder cancer). Detection of ubiquilin 2 in a urine sample allows easy and accurate diagnosis of a possibility of urothelial cancer. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).

Loading Nara Medical University collaborators
Loading Nara Medical University collaborators